Tag Archives: Pandemic

Women in 40s, 50s who survive COVID more likely to suffer persistent problems: UK studies

By Kate Kelland

LONDON (Reuters) – Women in their 40s and 50s appear more at risk of long-term problems following discharge from hospital after COVID-19, with many suffering months of persistent symptoms such as fatigue, breathlessness and brain fog, two UK studies found on Wednesday.

One study found that five months after leaving hospital, COVID-19 patients who were also middle-aged, white, female, and had other health problems such as diabetes, lung or heart disease, tended to be more likely to report long-COVID symptoms.

“Our study finds that those who have the most severe prolonged symptoms tend to be white women aged approximately 40 to 60 who have at least two long term health conditions,” said Chris Brightling, a professor of respiratory medicine at Leicester University who co-led the study known as PHOSP-COVID.

A second study led by the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) found that women under 50 had higher odds of worse long-term health outcomes than men and than older study participants, even if they had no underlying health conditions.

“It’s becoming increasingly clear that COVID-19 has profound consequences for those who survive the disease,” said Tom Drake, a clinical research fellow at Edinburgh University who co-led the ISARIC study.

“We found that younger women were most likely to have worse long-term outcomes.”

The ISARIC study, which covered 327 patients, found that women under 50 were twice as likely to report fatigue, seven times more likely to have breathlessness, and also more likely to have problems relating to memory, mobility and communication.

The PHOSP study analyzed 1,077 male and female patients who were discharged from hospitals in Britain between March and November 2020 after having COVID-19.

A majority of patients reported multiple persistent symptoms after 5 months, with common symptoms being muscle and joint pain, fatigue, weakness, breathlessness and brain fog.

More than a quarter had what doctors said were “clinically significant symptoms of anxiety and depression” at five months, and 12% had symptoms of post-traumatic stress disorder (PTSD).

Louise Wain, a professor and respiratory specialist at Leicester University who co-led PHOSP, said differences in male and female immune responses “may explain why post-COVID syndrome seems to be more prevalent” in women.

“We…know that autoimmunity, where the body has an immune response to its own healthy cells and organs, is more common in middle-aged women,” she said, but “further investigation is needed to fully understand” the processes involved.

(Reporting by Kate Kelland; Editing by Bernadette Baum)

Austria delays reopening restaurants as COVID-19 cases rise

VIENNA (Reuters) – Austria has postponed the reopening of café, restaurant and bar terraces planned for March 27 due to rising coronavirus cases and is preparing for regions to adapt restrictions locally, the government said on Monday.

Infections have been increasing steadily since Austria loosened its third lockdown on Feb. 8 by letting non-essential shops reopen despite stubbornly high COVID-19 cases. A night-time curfew replaced all-day restrictions on movement.

The number of new infections reported rose above 3,500 on Friday, the highest level since early December, when cases were falling during the second national lockdown.

The government met with the governors of its nine provinces on Monday to review its plan to let terraces reopen next weekend in all but one of them, after the small Alpine province of Vorarlberg got a head start earlier this month.

“The experts have advised us not to carry out any more loosening of restrictions here, unfortunately,” Chancellor Sebastian Kurz said of most provinces, adding three hard-hit eastern ones including Vienna would work on extra measures.

A government source said loosening of restrictions could happen in some regions after Easter if intensive-care figures are stable.

Last week the hardest-hit provinces were Vienna and the province surrounding it, Lower Austria, as well as Burgenland, which borders Hungary. The latest government data shows them in the top five in terms of infection rates and intensive care bed use, with Salzburg and Upper Austria.

(Reporting by Francois Murphy; Editing by Andrew Cawthorne and Janet Lawrence)

New U.S. COVID-19 cases show weekly uptick for first time since January

(Reuters) – New cases of COVID-19 in the United States rose 5% to more than 394,000 last week, the first increase after declining for nine straight weeks, according to a Reuters analysis of state, county and CDC data.

Thirty out of 50 states reported more new infections in the week ended March 21 compared with the previous seven days, up from 19 states in the prior week, according to the Reuters analysis.

Nationally, the weekly number of new cases had been on a downward trend since January, though health authorities have warned that infections could surge again if Americans relaxed social distancing restrictions too quickly. More infectious variants have also spread across the country.

“I am worried that if we don’t take the right actions now we will have another avoidable surge just as we are seeing in Europe right now and just as we are so aggressively scaling up vaccinations,” said Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, on Monday.

The Northeast logged some of the highest rates of infection per capita, led by New Jersey, New York and Rhode Island.

Deaths from COVID fell 15% to 7,793 last week, or about 1,100 per day, according to the Reuters analysis. Health officials hope the country’s vaccination effort can prevent a rise in deaths even if cases surge again.

For a fourth week, daily average vaccinations set a record, with 2.5 million shots given per day last week. As of Sunday, 25% of the U.S. population has received at least one dose of a vaccine, up from 21% a week ago, according to the Centers for Disease Control and Prevention. About 13% has received two doses, up from 11%.

The average number of COVID-19 patients in U.S. hospitals fell 6% to 36,000, the lowest since October, according to a Reuters tally.

Hospitalizations have fallen for 10 weeks nationally, but they are rising in 18 states, up from four states the previous week.

(Graphic by Chris Canipe, writing by Lisa Shumaker, editing by Tiffany Wu)

AstraZeneca vaccine safe and effective in new trial data

FRANKFURT/LONDON (Reuters) – AstraZeneca’s COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States, the company said on Monday, paving the way for it to apply for U.S. approval.

The vaccine was also 100% effective against severe or critical disease and hospitalization, and was safe, the partners said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

The data will give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the data.

It will also help to allay safety concerns that have disrupted its use in the European Union after a small number of reports of rare blood clots in people who received the vaccine.

After briefly halting its use, many European countries have resumed using the shot in their inoculation programs after a regional regulator said it was safe, while several country leaders are also taking the vaccine to boost confidence.

AstraZeneca said an independent safety committee conducted a specific review of the blood clots in the U.S. trial, as well as cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, with the help of an independent neurologist.

The London-listed company said the panel found “no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

“These results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results from Oxford-led trials,” Andrew Pollard, who runs the Oxford Vaccine Group, said.

AstraZeneca said it was preparing to submit the data to the U.S. Food and Drug Administration and for a launch in the United States should it win Emergency Use Authorization.

University of Oxford professor Sarah Gilbert told BBC radio that work to prepare the submission will take a few weeks.

The efficacy read-out was above a rate of about 60%, cited by the European Union’s drugs regulator in its December recommendation.

It was, however, in line with the maximum efficacy found by Britain’s Medicines and Healthcare products Regulatory Agency (MHRA), based on cases with a three-month gap between the first and the second dose.

In the trial, participants received either two standard doses of the Oxford-AstraZeneca vaccine or a placebo vaccine, at a four-week interval.

Amongst participants in the interim analysis, about 79% were white/Caucasian, 8% black/African American, 4% native American and 4% Asian, and 22% of participants were Hispanic, the company said.

About 20% of participants were 65 years and over, and approximately 60% had co-morbidities associated with an increased risk for progression of severe COVID-19, such as diabetes, severe obesity or cardiac disease.

(Reporting by Ludwig Burger in Frankfurt, Pushkala Aripaka and Muvija M in Bengaluru; Editing by Josephine Mason, Mark Potter, Sherry Jacob-Phillips and Edmund Blair)

Keep using AstraZeneca vaccine, WHO urges world

By Emma Farge

GENEVA (Reuters) – The World Health Organization (WHO) exhorted the world to keep administering AstraZeneca’s COVID-19 shots on Friday, adding its endorsement to that of European and British regulators after concerns over blood clotting.

“We urge countries to continue using this important COVID-19 vaccine,” WHO Director General Tedros Adhanom Ghebreyesus told a news conference in Geneva.

He was speaking after the global health body’s vaccine safety panel said available data about the AstraZeneca shot did not point to any overall increase in clotting conditions.

European and British regulators also said this week that the benefits of AstraZeneca’s shot outweighed the risks, prompting various nations to lift their suspensions.

“The AstraZeneca vaccine is especially important because it accounts for more than 90% of the vaccines being distributed through COVAX,” Tedros added, referring to a WHO-led global vaccine-sharing scheme.

“There is no question. COVID-19 is a deadly disease, and the Oxford-AstraZeneca vaccine can prevent it. It’s also important to remember that COVID-19 itself can cause blood clots and low platelets.”

The WHO’s global advisory committee on vaccine safety said in a statement that the AstraZeneca vaccine had a “positive benefit-risk profile” and “tremendous potential” to prevent infections and reduce deaths.

The WHO panel of 12 independent experts, who met virtually on Tuesday and on Thursday, reviewed safety data from Europe, the United Kingdom, India, and WHO’s global database.

“While very rare and unique thromboembolic events in combination with thrombocytopenia, such as cerebral venous sinus thrombosis (CVST), have also been reported following vaccination with the AstraZeneca COVID-19 vaccine in Europe, it is not certain that they have been caused by vaccination,” it said.

(Reporting by Michael Shields, Emma Farge and Stephanie Nebehay; Writing by Andrew Cawthorne; Editing by Hugh Lawson)

Europe becomes first region to surpass 1 million COVID-19 deaths: Reuters tally

By Shaina Ahluwalia and Roshan Abraham

(Reuters) – Coronavirus-related deaths in the European region surpassed 1 million on Friday as vaccination efforts attempt to keep up with new variants causing a third wave of infections that could once again overwhelm hospitals.

Since the pandemic began, at least 37,221,978 infections and 1,000,062 deaths were reported in the European region, according to a Reuters tally.

The region, which includes 51 countries, has about 35.5% of all coronavirus deaths and 30.5% of all cases in the world. The region includes Russia, the United Kingdom, the 27 members of the European Union and other countries.

The European region has administered about 12 vaccine shots for every 100 people, behind the United States which has administered about 34 doses per 100 people, according to figures from Our World in Data. Israel leads the world in vaccination efforts with about 110 shots given for every 100 individuals. Some vaccines require two doses.

With the number of EU COVID-19 related deaths above 550,000 and less than a tenth of the population inoculated, European Commission head Ursula von der Leyen said the situation was worsening. “We see the crest of a third wave forming in member states, and we know that we need to accelerate the vaccination rates.”

On Wednesday, the European Union threatened to ban exports of COVID-19 vaccines to Britain to safeguard scarce doses for its own citizens.

The number of infections in Europe have started picking up, with France recently seeing its biggest one-day jump in cases since November. The region is currently reporting a million new cases about every six days.

As Germany plans to lift the lockdown and revive its economy, an expert at the Robert Koch Institute for infectious diseases said on Tuesday that the number of infections is rising exponentially, with the country entering a third wave of the pandemic.

As the European Union looks to meet its summer target of inoculating 70% of adults, at least 13 countries in the bloc have suspended or delayed using AstraZeneca’s COVID-19 vaccine after reports of blood coagulation in people who have received the shot.

Countries in eastern Europe, including Russia, remain the worst-affected based on the total number of cases and deaths.

Russia has the highest total number of COVID infections, with over 4.4 million or nearly 12% of all the cases in the region. The country has one of the highest COVID-19 fatality rates in the world on a per capita basis, with about 153 deaths per 100,0000 residents, behind the United States with 164 deaths for every 100,000 people.

While the official death toll in Russia stands at 94,267, at least 221,534 have perished due to the disease, according to a Reuters calculation which includes deaths reported by the country’s Rosstat statistics agency.

Italy became the third country in Europe to exceed more than 100,000 deaths last week. Prime Minister Mario Draghi warned that the situation would worsen again with a jump in hospitalizations.

The World Health Organization appealed to the governments not to pause vaccination campaigns, while the European Medicines Agency has said that the number of thromboembolic events in vaccinated people is no higher than the number seen in the general population.

(Reporting by Shaina Ahluwalia and Roshan Abraham in Bengaluru; Editing by Lisa Shumaker)

Sweden reports 5,735 new COVID-19 cases, 26 deaths on Friday

STOCKHOLM (Reuters) – Sweden, which has shunned lockdowns throughout the pandemic, registered 5,735 new coronavirus cases on Friday, health agency statistics showed.

The country of 10 million inhabitants registered 26 new deaths, taking the total to 13,262. The deaths registered have occurred over several days and sometimes weeks.

Sweden’s death rate per capita is many times higher than that of its Nordic neighbors’ but lower than in several European countries that opted for lockdowns.

(Reporting by Johan Ahlander, Editing by Helena Soderpalm)

Mexico to tighten borders against COVID-19 as U.S. offers vaccine help

MEXICO CITY (Reuters) – Mexico’s government said on Thursday it would apply travel curbs on its southern border with Guatemala to help contain the spread of COVID-19 as officials said the Biden administration planned to loan Mexico vaccines to fight the pandemic.

The foreign ministry’s announcement that Mexico would restrict movement on its border with Guatemala comes just as the country plans to step up enforcement efforts in the area against illegal immigration, according to a Reuters report.

President Joe Biden is under increasing pressure to reduce a recent surge in migrants from Central America reaching the U.S. border while Mexico has been pressing the U.S. government for a loan of vaccines to help its drive to tackle COVID-19.

A U.S. congressional source said the mutually beneficial news on the vaccines and the border curbs was no coincidence. A Mexican official did not immediately reply to a request for comment on whether the two announcements were linked.

Confirming details reported by Reuters, Mexican Foreign Minister Marcelo Ebrard said that Mexico and the United States were crafting a deal for 2.5 million doses of AstraZeneca’s COVID-19 vaccine and that he would reveal more on Friday.

“This would be the best start for a broad cooperation on vaccines,” Ebrard said on Twitter.

A U.S. official told Reuters that under the loan deal, the United States would send Mexico 2.5 million doses of the AstraZeneca vaccine that it is not using. Canada is also set to receive 1.5 million doses under the arrangement.

In a statement, Mexico’s foreign ministry said restrictions for non-essential activities on its borders with the United States and Guatemala would take effect starting on Friday, and would remain in place until midnight of April 21.

During the past few months, Mexico had announced extensions to restrictions along its border with the United States as part of bilateral efforts to stem the spread of the pandemic.

Those monthly communiques did not mention the border with Guatemala, where average COVID-19 cases are now lower than they were in January, though they have been ticking up.

Mexico’s own infections have fallen sharply in the last few weeks, and the two southern states covering over 85% of the border with Guatemala are two of only three in the country at the lowest COVID-19 alert level, health ministry data show.

Mexico has 31 states.

(Reporting by Diego Ore and Dave Graham in Mexico City and Jeff Mason in Washington; Writing by Laura Gottesdiener; Editing by Andrea Ricci)

Canada extends travel restrictions at U.S. border: Canadian official

By David Shepardson

WASHINGTON (Reuters) – U.S. land borders with Canada will remain closed to non-essential travel until at least April 21, the Canadian government said Thursday.

The new 30-day extension is the second announced under President Joe Biden and comes as U.S lawmakers in border states have urged lifting the nearly year-old restrictions to address the COVID-19 pandemic.

Canada has shown little interest in lifting the restrictions and last month imposed new COVID-19 testing requirements for some Canadians returning at crossings.

(Reporting by David Shepardson; Editing by Chizu Nomiyama)

Disneyland theme parks in California to reopen April 30

(Reuters) – Walt Disney Co’s two theme parks in California will reopen on April 30 to a limited number of guests, the company said on Wednesday, over a year after they closed because of the COVID-19 pandemic.

Attendance will initially be capped at roughly 15% of capacity, Disney Chief Executive Bob Chapek said on CNBC television.

Advance reservations and an admission ticket will be required for entry. Guests age 2 and up will need to wear masks, except when eating, drinking or swimming, and follow other safety measures including temperature checks before entering and social distancing on rides and throughout the parks.

Under state guidelines, capacity may increase if the prevalence of coronavirus in the area continues to fall.

The Disneyland Resort, located in Anaheim 35 miles southeast of Los Angeles, closed in mid-March of 2020. The resort includes the original Disneyland, nicknamed “The Happiest Place on Earth,” and the adjacent California Adventure theme parks.

Florida’s Walt Disney World parks reopened to visitors in July 2020 and Disney officials had been urging the state of California to ease reopening restrictions.

(Reporting by Lisa Richwine in Los Angeles and Eva Mathews in Bengaluru; Editing by Richard Chang and Steve Orlofsky)